12 results on '"Verschelden, Gil"'
Search Results
2. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
- Author
-
Egle, Alexander, Greil, Richard, Joannidis, Michael, Lamprecht, Bernd, Altdorfer, Antoine, Belkhir, Leila, Fraipont, Vincent, Hites, Maya, Verschelden, Gil, Aboab, Jérôme, Ader, Florence, Ait-Oufella, Hafid, Andrejak, Claire, Andreu, Pascal, Argaud, Laurent, Bani-Sadr, Firouzé, Benezit, François, Blot, Mathieu, Botelho-Nevers, Elisabeth, Bouadma, Lila, Bouchaud, Olivier, Bougon, David, Bouiller, Kevin, Bounes-Vardon, Fanny, Boutoille, David, Boyer, Alexandre, Bruel, Cédric, Cabié, André, Canet, Emmanuel, Cazanave, Charles, Chabartier, Cyrille, Chirouze, Catherine, Clere-Jehl, Raphaël, Courjon, Johan, Crockett, Flora, Danion, François, Delbove, Agathe, Dellamonica, Jean, Djossou, Félix, Dubost, Clément, Duvignaud, Alexandre, Epaulard, Olivier, Epelboin, Loïc, Fartoukh, Murielle, Faure, Karine, Faure, Emmanuel, Ferry, Tristan, Ficko, Cécile, Figueiredo, Samy, Gaborit, Benjamin, Gaci, Rostane, Gagneux-Brunon, Amandine, Gallien, Sébastien, Garot, Denis, Geri, Guillaume, Gibot, Sébastien, Goehringer, François, Gousseff, Marie, Gruson, Didier, Hansmann, Yves, Hinschberger, Olivier, Jaureguiberry, Stéphane, Jeanmichel, Vanessa, Kerneis, Solen, Kimmoun, Antoine, Klouche, Kada, Lachâtre, Marie, Lacombe, Karine, Laine, Fabrice, Lanoix, Jean-Philippe, Launay, Odile, Laviolle, Bruno, Le Moing, Vincent, Le Pavec, Jérôme, Le Tulzo, Yves, Le Turnier, Paul, Lebeaux, David, Lefevre, Benjamin, Leroy, Sylvie, Lescure, François-Xavier, Lessire, Henry, Leveau, Benjamin, Loubet, Paul, Makinson, Alain, Malvy, Denis, Marquette, Charles-Hugo, Martin-Blondel, Guillaume, Martinot, Martin, Mayaux, Julien, Mekontso-Dessap, Armand, Meziani, Ferhat, Mira, Jean-Paul, Molina, Jean-Michel, Monnet, Xavier, Mootien, Joy, Mourvillier, Bruno, Murris-Espin, Marlène, Navellou, Jean-Christophe, Nseir, Saad, Oulehri, Walid, Peiffer-Smadja, Nathan, Perpoint, Thomas, Pialoux, Gilles, Pilmis, Benoît, Piriou, Vincent, Piroth, Lionel, Poissy, Julien, Pourcher, Valérie, Quenot, Jean-Pierre, Raffi, François, Reignier, Jean, Revest, Matthieu, Richard, Jean-Christophe, Riu-Poulenc, Béatrice, Robert, Céline, Roger, Pierre-Alexandre, Roger, Claire, Rouveix-Nordon, Elisabeth, Ruch, Yvon, Saidani, Nadia, Sayre, Naomi, Senneville, Eric, Sotto, Albert, Stefan, Francois, Tacquard, Charles, Terzi, Nicolas, Textoris, Julien, Thiery, Guillaume, Timsit, Jean-François, Tolsma, Violaine, Turmel, Jean-Marie, Valour, Florent, Wallet, Florent, Wattecamps, Guilhem, Yazdanpanah, Yazdan, Zerbib, Yoann, Berna, Marc, Reuter, Jean, Staub, Thérèse, Braz, Sandra, Ferreira Ribeiro, Joao-Miguel, Paiva, José-Artur, Roncon-Albuquerque, Roberto, Bouscambert-Duchamp, Maude, Gaymard, Alexandre, Lê, Minh-Patrick, Lina, Bruno, Peytavin, Gilles, Tubiana, Sarah, Couffin-Cadièrgues, Sandrine, Esperou, Hélène, Belhadi, Drifa, Burdet, Charles, Costagliola, Dominique, Dechanet, Aline, Delmas, Christelle, Diallo, Alpha, Fougerou, Claire, Guedj, Jérémie, Mentré, France, Mercier, Noémie, Noret, Marion, Saillard, Juliette, Velou, Priyanka, and Paiva, Jose-Artur
- Published
- 2022
- Full Text
- View/download PDF
3. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
- Author
-
Declercq, Jozefien, Van Damme, Karel F A, De Leeuw, Elisabeth, Maes, Bastiaan, Bosteels, Cedric, Tavernier, Simon J, De Buyser, Stefanie, Colman, Roos, Hites, Maya, Verschelden, Gil, Fivez, Tom, Moerman, Filip, Demedts, Ingel K, Dauby, Nicolas, De Schryver, Nicolas, Govaerts, Elke, Vandecasteele, Stefaan J, Van Laethem, Johan, Anguille, Sebastien, van der Hilst, Jeroen, Misset, Benoit, Slabbynck, Hans, Wittebole, Xavier, Liénart, Fabienne, Legrand, Catherine, Buyse, Marc, Stevens, Dieter, Bauters, Fre, Seys, Leen J M, Aegerter, Helena, Smole, Ursula, Bosteels, Victor, Hoste, Levi, Naesens, Leslie, Haerynck, Filomeen, Vandekerckhove, Linos, Depuydt, Pieter, van Braeckel, Eva, Rottey, Sylvie, Peene, Isabelle, Van Der Straeten, Catherine, Hulstaert, Frank, and Lambrecht, Bart N
- Published
- 2021
- Full Text
- View/download PDF
4. Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools.
- Author
-
Verschelden, Gil, Noeparast, Maxim, Stoefs, Anke, Van Honacker, Eveline, Vandoorslaer, Kristof, Vandervore, Laura, Olbrecht, Margo, Van Damme, Kathleen, Demuyser, Thomas, Piérard, Denis, and Wybo, Ingrid
- Subjects
DIFFUSION gradients ,DRUG resistance in microorganisms ,AZTREONAM ,GRAM-negative bacteria ,AGAR plates - Abstract
Introduction: Antimicrobial resistance is a growing problem that necessitates the development of new therapeutic options. Cefiderocol and aztreonam (AT) are often the last active β-lactams for treating metallo-β-lactamases (MBL)-producing Gram-negative bacilli. In these difficult-to-treat bacterial strains, AT resistance is frequently attributed to the co-occurrence of other resistance mechanisms. In the case of β-lactamases they can often be inhibited by avibactam. In the present study, we evaluated the use of the double-disc synergy test (DDST) as a screening tool for the detection of synergy between AT-avibactam (ATA). We validated both the Gradient Diffusion Strips (GDSs) superposition method and the commercially available Liofilchem’s ATA GDS. Materials and methods: We tested AT susceptibility in combination with ceftazidime-avibactam for 65 strains, including 18 Serine-β-Lactamase (SBL)- and 24 MBL-producing Enterobacterales, 12 MBL-producing P. aeruginosa, and 11 S. maltophilia isolates. Interpretation was done with EUCAST breakpoints (version 13.0), AT breakpoints being used for ATA. The accuracy and validity of the GDSs superposition method and ATA GDS were evaluated using an AT GDS applied on Mueller Hinton Agar plates supplemented with avibactam (MH-AV). A DDST was performed to screen for synergy between antibiotic combinations. Results: Using MH-AV, all SBL- and MBL-positive Enterobacterales were susceptible or susceptible at increased exposure to the combination AT-avibactam. In contrast, only 2 out of the 12 (17%) P. aeruginosa strains and 9/11 (82%) of the S. maltophilia strains were susceptible- or susceptible at increased exposure for the combination of AT-avibactam. The DDST detected all synergies, demonstrating a 100% sensitivity and 100% negative predictive value for all bacterial strains. Conclusion: The DDST is a sensitive tool for screening for antibiotic synergy. Unlike S. maltophilia and SBL- and MBL-positive Enterobacterales, most MBLpositive P. aeruginosa strains remain resistant to AT-avibactam. ATA GDS should be preferred for MIC determination of the AT-avibactam combination, while the GDSs superposition method can be used as an alternative to the commercial test. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Analysis of a Combined HBHA and ESAT-6-Interferon-γ-Release Assay for the Diagnosis of Tuberculous Lymphadenopathies.
- Author
-
Mascart, Françoise, Hites, Maya, Watelet, Emmanuelle, Verschelden, Gil, Meuris, Christelle, Doyen, Jean-Luc, Van Praet, Anne, Godefroid, Audrey, Petit, Emmanuelle, Singh, Mahavir, Locht, Camille, and Corbière, Véronique
- Subjects
TUBERCULOSIS ,LYMPHADENITIS ,BACTERIAL antigens ,DIAGNOSIS ,DIFFERENTIAL diagnosis - Abstract
Background and Objectives: The incidence of tuberculosis lymphadenopathy (TBLA) is increasing, and diagnostic procedures lack sensitivity and are often highly invasive. TBLA may be asymptomatic, and differential diagnosis with other adenopathies (ADPs) is difficult. We evaluated a blood-cell interferon-γ release assay (IGRA) with two different stage-specific mycobacterial antigens for the differential diagnosis of ADP suspected of mycobacterial origin. Methods: Twenty-one patients were included and divided into three groups: (1) cervical/axillar ADP (n = 8), (2) mediastinal ADP (n = 10), and (3) disseminated ADP (n = 3). The mycobacterial antigens used for the IGRA were the heparin-binding haemagglutinin (HBHA) and the early-secreted antigenic target-6 (ESAT-6), a latency-associated antigen and a bacterial replication-related antigen, respectively. Diagnosis of TBLA based on microbiological results and/or response to anti-TB treatment was obtained for 15 patients. Results: An IGRA profile highly suggestive of active TB (higher IFN-γ response to ESAT-6 compared to HBHA) was found for 3/6 TBLA patients from group 1, and for all the TBLA patients from groups 2 and 3, whereas this profile was not noticed in patients with a final alternative diagnosis. Conclusion: These results highlight the potential value of this combined HBHA/ESAT-6 IGRA as a triage test for the differential diagnosis of ADP. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19
- Author
-
Aboab, Jérôme, Ader, Florence, Ait-Oufella, Hafid, Altdorfer, Antoine, Andrejak, Claire, Andreu, Pascal, Argaud, Laurent, Bani-Sadr, Firouzé, Belhadi, Drifa, Belkhir, Leila, Benezit, François, Berna, Marc, Blot, Mathieu, Botelho-Nevers, Elisabeth, Bouadma, Lila, Bouchaud, Olivier, Bougon, David, Bouiller, Kevin, Bounes-Vardon, Fanny, Bouscambert-Duchamp, Maude, Boutoille, David, Boyer, Alexandre, Braz, Sandra, Bruel, Cédric, Burdet, Charles, Cabié, André, Canet, Emmanuel, Cazanave, Charles, Chabartier, Cyrille, Chirouze, Catherine, Clere-Jehl, Raphaël, Costagliola, Dominique, Couffin-Cadièrgues, Sandrine, Courjon, Johan, Crockett, Flora, Danion, François, Dechanet, Aline, Delbove, Agathe, Dellamonica, Jean, Delmas, Christelle, Diallo, Alpha, Djossou, Félix, Dubost, Clément, Duvignaud, Alexandre, Egle, Alexander, Epaulard, Olivier, Epelboin, Loïc, Esperou, Hélène, Fartoukh, Murielle, Faure, Karine, Faure, Emmanuel, Ferreira Ribeiro, Joao-Miguel, Ferry, Tristan, Ficko, Cécile, Figueiredo, Samy, Fougerou, Claire, Fraipont, Vincent, Gaborit, Benjamin, Gaci, Rostane, Gagneux-Brunon, Amandine, Gallien, Sébastien, Garot, Denis, Gaymard, Alexandre, Geri, Guillaume, Gibot, Sébastien, Goehringer, François, Gousseff, Marie, Greil, Richard, Gruson, Didier, Guedj, Jérémie, Hansmann, Yves, Hinschberger, Olivier, Hites, Maya, Jaureguiberry, Stéphane, Jeanmichel, Vanessa, Joannidis, Michael, Kerneis, Solen, Kimmoun, Antoine, Klouche, Kada, Lachâtre, Marie, Lacombe, Karine, Laine, Fabrice, Lamprecht, Bernd, Lanoix, Jean-Philippe, Launay, Odile, Laviolle, Bruno, Lê, Minh-Patrick, Le Moing, Vincent, Le Pavec, Jérôme, Le Tulzo, Yves, Le Turnier, Paul, Lebeaux, David, Lefevre, Benjamin, Leroy, Sylvie, Lescure, François-Xavier, Lessire, Henry, Leveau, Benjamin, Lina, Bruno, Loubet, Paul, Makinson, Alain, Malvy, Denis, Marquette, Charles-Hugo, Martin-Blondel, Guillaume, Martinot, Martin, Mayaux, Julien, Mekontso-Dessap, Armand, Mentré, France, Mercier, Noémie, Meziani, Ferhat, Mira, Jean-Paul, Molina, Jean-Michel, Monnet, Xavier, Mootien, Joy, Mourvillier, Bruno, Mourvilliers, Bruno, Murris-Espin, Marlène, Navellou, Jean-Christophe, Noret, Marion, Nseir, Saad, Oulehri, Walid, Paiva, José-Artur, Peiffer-Smadja, Nathan, Perpoint, Thomas, Peytavin, Gilles, Pialoux, Gilles, Pilmis, Benoît, Piriou, Vincent, Piroth, Lionel, Poissy, Julien, Pourcher, Valérie, Quenot, Jean-Pierre, Raffi, François, Reignier, Jean, Reuter, Jean, Revest, Matthieu, Richard, Jean-Christophe, Riu-Poulenc, Béatrice, Robert, Céline, Roger, Pierre-Alexandre, Roger, Claire, Roncon-Albuquerque, Roberto, Rouveix-Nordon, Elisabeth, Ruch, Yvon, Saidani, Nadia, Saillard, Juliette, Sayre, Naomi, Senneville, Eric, Sotto, Albert, Staub, Thérèse, Stefan, Francois, Tacquard, Charles, Terzi, Nicolas, Textoris, Julien, Thiery, Guillaume, Timsit, Jean-François, Tolsma, Violaine, Tubiana, Sarah, Turmel, Jean-Marie, Valour, Florent, Vardon-Bounes, Fanny, Velou, Priyanka, Verschelden, Gil, Wallet, Florent, Wattecamps, Guilhem, Yazdanpanah, Yazdan, and Zerbib, Yoann
- Published
- 2022
- Full Text
- View/download PDF
7. Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection.
- Author
-
Poncelet, Arthur, Verschelden, Gil, Colard, Martin, Hildebrand, Marc, Hites, Maya, Yin, Nicolas, Michel, Charlotte, Grimaldi, David, and De Wilde, Virginie
- Subjects
- *
MANTLE cell lymphoma , *SARS-CoV-2 , *COVID-19 , *FEBRILE neutropenia , *DIFFUSE large B-cell lymphomas , *CANCER chemotherapy - Abstract
In another study, no reactivation was documented following chemotherapy in patients previously infected with SARS-CoV-2, but all patients had negative SARS-CoV-2 PCR on NPS and positive SARS-CoV-2 serology before receiving chemotherapy [[11]]. Given the increased risk of infection after chemotherapy, hematological societies have proposed postponing chemotherapy, when feasible, during the COVID-19 pandemic [[1]], despite initial studies showing no increase in the incidence of COVID-19 among hematological patients [[2]]. It is noteworthy that all three patients had negative serology for SARS-CoV-2 more than one month after their first positive PCR for SARS-CoV-2, suggesting that these patients were not able to develop a humoral immune response against SARS-CoV-2. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
8. Presumed Urinary Tract Infection in Patients Admitted with COVID-19: Are We Treating Too Much?
- Author
-
Van Laethem, Johan, Wuyts, Stephanie C. M., Pierreux, Jan, Seyler, Lucie, Verschelden, Gil, Depondt, Thibault, Meuwissen, Annelies, Lacor, Patrick, Piérard, Denis, and Allard, Sabine D.
- Subjects
URINARY tract infections ,COVID-19 ,DRUGS ,COMMUNICABLE diseases ,DRUG prescribing - Abstract
Despite the low rates of bacterial co-/superinfections in COVID-19 patients, antimicrobial drug use has been liberal since the start of the COVID-19 pandemic. Due to the low specificity of markers of bacterial co-/superinfection in the COVID-19 setting, overdiagnosis and antimicrobial overprescription have become widespread. A quantitative and qualitative evaluation of urinary tract infection (UTI) diagnoses and antimicrobial drug prescriptions for UTI diagnoses was performed in patients admitted to the COVID-19 ward of a university hospital between 17 March and 2 November 2020. A team of infectious disease specialists performed an appropriateness evaluation for every diagnosis of UTI and every antimicrobial drug prescription covering a UTI. A driver analysis was performed to identify factors increasing the odds of UTI (over)diagnosis. A total of 622 patients were included. UTI was present in 13% of included admissions, and in 12%, antimicrobials were initiated for a UTI diagnosis (0.71 daily defined doses (DDDs)/admission; 22% were scored as 'appropriate'). An evaluation of UTI diagnoses by ID specialists revealed that of the 79 UTI diagnoses, 61% were classified as probable overdiagnosis related to the COVID-19 hospitalization. The following factors were associated with UTI overdiagnosis: physicians who are unfamiliar working in an internal medicine ward, urinary incontinence, mechanical ventilation and female sex. Antimicrobial stewardship teams should focus on diagnostic stewardship of UTIs, as UTI overdiagnosis seems to be highly prevalent in admitted COVID-19 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study.
- Author
-
Verschelden, Gil, Noeparast, Maxim, Noparast, Maryam, Goossens, Mathijs Christiaan, Lauwers, Maïlis, Cotton, Frédéric, Michel, Charlotte, Goyvaerts, Cleo, and Hites, Maya
- Subjects
- *
COVID-19 , *ADULT respiratory distress syndrome , *ZINC , *HOSPITAL patients , *CYTOKINE release syndrome - Abstract
• The majority of hospitalized COVID-19 patients are zinc deficient. • There is a weak correlation between plasma zinc and the length of hospital stay. • cHIS score, described by Webb et al., is externally validated in this study. • Current findings do not support plasma zinc as a robust prognostic factor. Zinc deficiency is associated with impaired antiviral response, cytokine releasing syndrome (CRS), and acute respiratory distress syndrome. Notably, similar complications are being observed during severe SARS-CoV-2 infection. We conducted a prospective, single-center, observational study in a tertiary university hospital (CUB-Hôpital Erasme, Brussels) to address the zinc status, the association between the plasma zinc concentration, development of CRS, and the clinical outcomes in PCR-confirmed and hospitalized COVID-19 patients. One hundred and thirty-nine eligible patients were included between May 2020 and November 2020 (median age of 65 years [IQR = 54, 77]). Our cohort's median plasma zinc concentration was 57 µg/dL (interquartile range [IQR] = 45, 67) compared to 74 µg/dL (IQR = 64, 84) in the retrospective non-COVID-19 control group (N = 1513; p < 0.001). Markedly, the absolute majority of COVID-19 patients (96%) were zinc deficient (<80 µg/dL). The median zinc concentration was lower in patients with CRS compared to those without CRS (-5 µg/dL; 95% CI = -10.5, 0.051; p = 0.048). Among the tested outcomes, zinc concentration is significantly correlated with only the length of hospital stay (rho = -0.19; p = 0.022), but not with mortality or morbidity. As such, our findings do not support the role of zinc as a robust prognostic marker among hospitalized COVID-19 patients who in our cohort presented a high prevalence of zinc deficiency. It might be more beneficial to explore the role of zinc as a biomarker for assessing the risk of developing a tissue-damaging CRS and predicting outcomes in patients diagnosed with COVID-19 at the early stage of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation: a case report and literature review.
- Author
-
Verschelden, Gil, Van Laethem, Johan, and De Grève, Jacques
- Published
- 2019
11. Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation.
- Author
-
Verschelden G, Van Laethem J, Velkeniers B, Ilsen B, Noeparast A, and De Grève J
- Subjects
- Erdheim-Chester Disease genetics, Erdheim-Chester Disease metabolism, Humans, Imidazoles pharmacology, Male, Middle Aged, Oximes pharmacology, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Treatment Outcome, Erdheim-Chester Disease drug therapy, Imidazoles therapeutic use, Mutation, Missense, Oximes therapeutic use, Proto-Oncogene Proteins B-raf genetics
- Published
- 2018
- Full Text
- View/download PDF
12. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.
- Author
-
Noeparast A, Teugels E, Giron P, Verschelden G, De Brakeleer S, Decoster L, and De Grève J
- Abstract
Approximately half of BRAF-mutated Non-small cell lung cancers (NSCLCs) harbor a non-V600 BRAF mutation, accounting for ∼40,000 annual deaths worldwide. Recent studies have revealed the benefits of combined targeted therapy with a RAF-inhibitor (Dabrafenib) and a MEK-inhibitor (Trametinib) in treating V600 BRAF mutant cancers, including NSCLC. In contrast, sensitivity of non-V600 BRAF mutations to these inhibitors is not documented. Non-V600 mutations can either increase or impair BRAF kinase activity. However, impaired BRAF kinases can still activate the ERK pathway in a CRAF-dependent manner. Herein, beyond describing a cohort of BRAF mutant NSCLC patients and functionally analyzing 13 tumor-derived BRAF mutations, we demonstrate that both types of non-V600 BRAF mutations can be sensitive to clinically relevant doses of Dabrafenib and Trametinib in HEK293T cells, in lung epithelial cellular model (BEAS-2B) and in human cancer cell lines harboring non-V600 BRAF mutations. ERK activity induced by both types of these mutations is further reduced by combinatorial drug treatment. Moreover, the combination leads to more prolonged ERK inhibition and has anti-proliferative and pro-apoptotic effects in cells harboring both types of non-V600 BRAF mutations. This study provides a basis for the clinical exploration of non-V600 BRAF mutant lung cancers upon treatment with Trametinib and Dabrafenib., Competing Interests: CONFLICTS OF INTEREST Authors claim no conflicts of interest
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.